Vertex and CRISPR Therapeutics Report Real-World Outcomes for Casgevy in Beta-Thalassemia

Vertex Pharmaceuticals and CRISPR Therapeutics today presented real-world outcomes data for Casgevy (exagamglogene autotemcel) in patients with transfusion-dependent beta-thalassemia treated in clinical practice. The data showed that all patients who received Casgevy achieved transfusion independence, consistent with clinical trial results. These real-world data confirm the transformative potential of Casgevy gene therapy in beta-thalassemia.